Perceptive Xontogeny Venture
Venture capitalNew York
Also known as Perceptive Xontogeny Venture SLP
Fund manager profile
Perceptive Xontogeny Venture is a venture fund manager based in New York. SEC filings show 4 venture funds on record, most recently Perceptive Xontogeny Venture Fund II, LP ($515M offering) filed May 2021.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 4 of 4 portfolio companiesBiotech ×3AI & Machine Learning ×1EdTech ×1Enterprise Software ×1Future of Work ×1Healthtech ×1Medical Devices ×1
HQs:United States×4
Investments · 4 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 13 dated
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsThird Rock Ventures
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)Steve Anheier(Executive Officer)
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
Co-investorsOCV PartnersCowen Healthcare InvestmentsGoldman SachsVertex Ventures HC
Portfolio news
latest coverage across their companies
Galvanize · muonspace.com · Aug 20, 2026
TORL BioTherapeutics · endpoints.news · Oct 7, 2025
Galvanize Therapeutics · fiercebiotech.com · Sep 4, 2025
CARGO Therapeutics · finance.yahoo.com · Jul 29, 2025
Frequently asked questions
- Where is Perceptive Xontogeny Venture located?
- Perceptive Xontogeny Venture is headquartered in New York, US.